Current Report Filing (8-k)
10 June 2023 - 6:06AM
Edgar (US Regulatory)
0001557376
false
0001557376
2023-06-07
2023-06-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): June 7, 2023
ORGANICELL REGENERATIVE MEDICINE, INC.
(Exact
name of registrant as specified in its charter)
Nevada |
|
000-55008 |
|
47-4180540 |
(State
or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
3321 College Avenue, Suite 246
Davie,
Florida |
|
33314 |
(Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (888) 963-7881
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each Class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
None |
|
N/A |
|
N/A |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
As
used in this Current Report on Form 8-K (this “Report”), and unless otherwise indicated, the terms “the
Company,” “Organicell,” “we,” “us” and “our” refer
to Organicell Regenerative Medicine, Inc. and its subsidiaries.
| Item
8.01 | Other
Information. |
On
June 7, 2023, Organicell filed a four-count complaint with the Seventeenth Judicial Circuit in and for Broward County, Florida against
Albert Mitrani and Dr. Maria Ines Mitrani, co-founders of the Company. Albert Mitrani was a former director and executive officer of
the Company (most recently serving as Chief Executive Officer from September 2019 to July 2022 and as Executive Vice President of Sales
from July 2022 until his termination in May 2023) and Dr. Mitrani is a current director and former executive officer of the Company (serving
as Chief Science Officer from November 2016 until her termination in April 2023). The complaint alleges (i) breach of contract; (ii)
breach of fiduciary duty; and (iii) tortious interference with business relationships; and seeks injunctive relief, in connection with,
inter alia, non-solicitation and non-competition violations, misappropriation of Organicell materials and proprietary information
resulting in unjust enrichment, causing detriment to business relationships and goodwill towards customers and physicians, self-dealing
and misconduct afoul to Organicell’s business interests as members of Organicell’s board of directors, executive officers
and minority equity interest holders—all causing irreparable harm to Organicell. The complaint seeks injunctive relief, in addition
to both compensatory and punitive damages.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated: June 9,
2023 |
ORGANICELL
REGENERATIVE MEDICINE, INC. |
|
|
|
By: |
/s/
Ian Bothwell |
|
|
Ian Bothwell
Chief Financial Officer |
Organicell Regenerative ... (QB) (USOTC:OCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Organicell Regenerative ... (QB) (USOTC:OCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024